Bookmark

Add to MyYahoo RSS

Abbott Labs News

News on Abbott Labs (Ticker: ABT) continually updated from thousands of sources around the net.

Thursday | Law.com

After deciding to forgo its own request for rehearing of the Ninth...

After deciding to forgo its own request for rehearing of the Ninth Circuit's decision prohibiting a party from striking a juror based on sexual orientation, Abbott Labs.

Comment?

Thursday Apr 17 | Benzinga

Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories .

Comment?

Related Topix: Absolute Software, Facet Biotech, Abbott Laboratories, Software

Wed Apr 16, 2014

The Washington Post

Abbott First-Quarter Profit Beats Estimates on Diagnostics

Abbott Laboratories, the largest maker of heart stents and adult nutritional beverages, said first-quarter profit beat dampened expectations, with only the diagnostic unit turning in higher sales.

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software, Investment Banking, Financial Services, Jefferies Group, Investment Services, Business News

TheStreet.com

Abbott Labs' Beats on Adjusted Basis Despite Drop in Net Income

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Mozilla

AmericanBankingNews.com

Abbott Laboratories (ABT) Posts Quarterly Results

Abbott Laboratories posted its quarterly earnings results on Wednesday. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.05, Analyst Ratings.Net reports.

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software

Reuters

Abbott Laboratories beats profit forecast, sales lags

Abbott Laboratories Inc reported better-than-expected earnings in the first quarter on Wednesday, but sales came in slightly below Wall Street expectations.

Comment?

Related Topix: Absolute Software, Facet Biotech, Abbott Laboratories, Software

Reuters

UPDATE 1-Abbott Laboratories beats profit forecast, sales lags

Abbott Laboratories Inc reported better-than-expected earnings in the first quarter on Wednesday, but sales came in slightly below Wall Street expectations.

Comment?

Related Topix: Absolute Software, Facet Biotech, Abbott Laboratories, Software

Tue Apr 15, 2014

Forbes.com

Abbott Earnings Preview: Emerging Markets & New Products Likely To Drive Sales

Abbott Labs is scheduled to release its Q1 2014 earnings on Wednesday, April 16. In the previous quarter, operational sales increased 3.3% year-over-year to $5.7 billion, driven by robust sales of its Diagnostics, Vascular and Medical Optics products.

Comment?

Related Topix: Financial Markets

AmericanBankingNews.com

Abbott Laboratories (ABT) Scheduled to Post Earnings on Wednesday

Abbott Laboratories is scheduled to be releasing its Q114 earnings data on Wednesday, April 16th.

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software

Mon Apr 14, 2014

Barron's

New Drug Cocktail Should Boost AbbVie Shares

Along with similar strides made by rivals Merck & Co. and Bristol-Myers Squibb , the results constitute one of the biggest recent...

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software, Biotech, Merck , Medicine, Healthcare Industry

Mon Apr 07, 2014

The Telegraph

Deal nudge to consolidation

Acquisitions by foreigners include the sale of the domestic formulation business of Piramal Healthcare to Abbott Laboratories in 2010 and Shanta Biotechnics to Sanofi-Aventis in 2009.

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software, World News, India, Asia

BioSpace

AbbVie To Host First-Quarter Earnings Conference Call

Eastern). It will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com .

Comment?

Related Topix: Absolute Software, Facet Biotech, Abbott Laboratories, Software

Fri Apr 04, 2014

Seeking Alpha

Abbott Laboratories: This Company Has Potential To Expand Into Emerging Markets

The company is turning its focus on emerging markets to cater to the rising demand in those countries for basic products such as nutrition supplements and generic drugs.

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software

Mon Mar 31, 2014

The Motley Fool

Special Situation Alert: Time to Buy a Biotech Breakup?

It appears Baxter is no longer content to spin off underperforming units, but is instead taking a long-hoped-for dramatic reshaping to unlock value for shareholders.

Comment?

Related Topix: Biotech, Biogen Idec, The Motley Fool

GuruFocus.com

Absolute and Relative Valuation Models Indicate the Same: Abbot Is a Buy

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of health care products.

Comment?

Related Topix: Absolute Software, Facet Biotech, Abbott Laboratories, Software

Customer Interaction Solutions

Global Protein Therapeutics Market 2012-2016: Patent-Expiration of...

Dublin - Research and Markets has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering.

Comment?

Related Topix: Outsourcing, Pegasys, Startups, Five Prime Therapeutics, Biotech, Medicine, Amgen, Healthcare Industry, Facet Biotech

Fri Mar 28, 2014

GuruFocus.com

We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies

Baxter International Inc. develops, manufactures and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

Comment?

Related Topix: Medicine, Baxter International, Medical Equipment, Healthcare Industry, Hemophilia, Health, Facet Biotech, Absolute Software, Abbott Laboratories, Software

Thu Mar 27, 2014

PR-inside.com

New Report Available: Investigation Report on China Adalimumab Market, 2010-2018

Description Adalimumab is a TNF inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA.

Comment?

Related Topix: Facet Biotech, Absolute Software, Abbott Laboratories, Software, Crohn's Disease, Health, Marketing

Wed Mar 26, 2014

BioSpace

AbbVie CEO's Pay Doubles In Firm's First Year

AbbVie Inc. CEO and Chairman Richard Gonzalez's pay more than doubled to $18.2 million in 2013, the first year after the North Chicago-based drug company's spinoff from Abbott Labs.

Comment?

Fri Mar 21, 2014

Customer Interaction Solutions

China Adalimumab Market Investigation Report with 2018 Forecasts Now...

Dallas, TX March 22, 2014 Adalimumab is a TNF inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA.

Comment?

Related Topix: Dallas, TX, Biotech, Cambridge Antibody Technology Group, Facet Biotech, Absolute Software, Abbott Laboratories, Software

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••